) -- European regulators recommended approval for a slew of drugs Friday that are already cleared for sale on this side of the Atlantic Ocean.
These drugs are:
The lupus drug Benlysta, developed by Human Genome Sciences and marketing partner GlaxoSmithKline .
Victrelis, the new hepatitis C drug from Merck , which received U.S. approval one week ago.
Xgeva, Amgen's drug for the treatment of bone complications due to cancer.
Yervoy, the melanoma drug from Bristol-Myers Squibb .
Fampyra, a drug used to improve the walking ability of patients with multiple sclerosis marketed by Biogen Idec but developed by Acorda Therapeutics . EU regulators granted conditional approval to Fampyra after initially rejecting the drug last year. Biogen and Acorda will be required to submit additional efficacy and safety data to EU regulators.
--Written by Adam Feuerstein in Boston.
>To contact the writer of this article, click here:
>To follow the writer on Twitter, go to
>To submit a news tip, send an email to:
Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback;
to send him an email.